Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPLT3 risk-stratified phase II trial for non-metastatic hepatoblastoma
jRCTs061180086Phase 2Completed
- Start
- Sep 2012
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin and doxorubicin in hepatoblastoma (2 arms). Primary endpoint: 3-year progression-free survival. Started Sep 2012; status: completed.
02
Drugs
cisplatindoxorubicin
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on jRCTs061180086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061180086.